A study investigating 96 patients who received NAT showed that even though serum NfL levels at therapy initiation were similar in patients who later developed PML and patients who did not, NfL levels were reduced in both groups during treatment. This evidence concerns the gene BRD2 and progressive multifocal leukoencephalopathy.